Squamous-cell carcinoma

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Retrieved on: 
Thursday, March 21, 2024
Stroke, Netherlands Cancer Institute, Conference, Development, Immunotherapy, GSK, Patient, Lung, DSM-IV codes, National Cancer Institute, MD Anderson Cancer Center, University, Doctor of Philosophy, NIH, Senior, Sarcoma, Clinical trial, Annual report, Bangladesh Technical Education Board, Squamous-cell carcinoma, OCCC, Pharmaceutical industry

PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.

Key Points: 
  • -- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --
    PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.
  • The clinical trial was initiated by, and is being conducted at, the University of Texas MD Anderson Cancer Center.
  • Dr. Bernards is a member of the Board of Directors of LIXTE.

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Retrieved on: 
Tuesday, February 27, 2024
Head, Neoplasm, DCR, Cetuximab, ESMO, Aes, Drug resistance, Escape Room, Immunotherapy, SCCHN, University, Nausea, Squamous-cell carcinoma, Tumor microenvironment, Patient, Congress, HPV, Plasma, Colorectal cancer, Pharmaceutical industry

REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced clinical results from its Phase 1/2 dose escalation study of NT219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer (R/M SCCHN).

Key Points: 
  • The Phase 1/2 dose escalation study (NCT04474470) evaluated NT219 as a monotherapy in various indications and in combination with cetuximab in the treatment of R/M SCCHN and colorectal cancer.
  • As of cut-off date of January 25, 2024:
    Seventeen patients with R/M SCCHN were enrolled in the combination arm of NT219 + cetuximab.
  • The median number of prior lines of therapy was 2 and 94% of the patients received prior immunotherapy.
  • “We were encouraged to see anti-tumor activity in HPV negative patients,” said Dr. Michael Schickler, Purple Biotech’s Head of Clinical and Regulatory Affairs.

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
Wednesday, February 21, 2024
Head, Breast cancer, Neck, Cancer, Woman, Survivor, Diet, Reproductive medicine, Assistant, Melanoma, Blood, Uterus, Biostatistics, Skin, Immunodeficiency, Database, Communication, Risk, FACP, Breast, University, Stomach, Vaccination, MD Anderson Cancer Center, Member of Congress, Genetic, Dicarboxylic acid, Drinking, Ovarian cancer, Genetics, Squamous-cell carcinoma, Death, Associate, Genetic testing, Black, Huntsman Cancer Institute, SCCS, Disease, HPV, Knowledge, Health literacy, Mortality, New York University, Research, University of North Carolina, Partnership, Birth control

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Retrieved on: 
Thursday, February 1, 2024
Tumor microenvironment, Standard of care, SCCHN, Pharmacokinetics, Congress, Head, Patient, Safety, Drug resistance, STAT3, Concept, Neck, ESMO, Neoplasm, Squamous-cell carcinoma, Escape Room, Cetuximab, Pharmaceutical industry

REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment of head and neck cancer based on its Phase 1/2 dose escalation study (NCT04474470).

Key Points: 
  • REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment of head and neck cancer based on its Phase 1/2 dose escalation study (NCT04474470).
  • The Company recently reported that NT219, in combination with cetuximab, demonstrated a dose dependent anti-tumor activity with confirmed partial responses.
  • The Company is now advancing its upcoming Phase 2 Proof of Concept study of NT219 for the treatment of R/M SCCHN.
  • “We look forward to treating more patients with NT219 in a Phase 2 study.”

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Retrieved on: 
Monday, January 29, 2024
Squamous-cell carcinoma, Patient, OCCC, Monroe Dunaway Anderson, MD Anderson Cancer Center, PD-1, GSK, Gynecologic Oncology (journal), Immunotherapy, University, Observation, Clinical trial, Pharmaceutical industry

The clinical trial was initiated by and is being conducted at The University of Texas MD Anderson Cancer Center.

Key Points: 
  • The clinical trial was initiated by and is being conducted at The University of Texas MD Anderson Cancer Center.
  • LIXTE is providing LB-100; GSK is providing dostarlimab-gxly and financial support for the clinical trial.
  • The clinical trial (NCT06065462) is based on the observation by the lead clinical investigator of the trial, Amir Jazaeri MD, Professor of Gynecologic Oncology at MD Anderson, that a genetically acquired reduction in PP2A may enhance sensitivity to immunotherapyi.
  • This raises the possibility that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody, dostarlimab-gxly, in patients with OCCC lacking the genetic reduction in PP2A.

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Well, Neck, Annual general meeting, DNA, Cervical cancer, Castration, ICI, PSA, ADC, Patient, Research, Lymph, E pluribus unum, Neoplasm, Cytokine, Cancer, Pembrolizumab, Oncology, Doctor of Philosophy, OS, Burtness, Webcast, Safety, Fourth grade, Food, Head, International, Radiation, PDS, Infection, Society, SOC, PDSB, KOL, Opinion, National Cancer Institute, IL12, Recurrence, CRT, CD8, Ferret, Nivolumab, Squamous-cell carcinoma, Biomarker, Standard works, HDAC, Clinical trial, NCI, FDA, Biotechnology, Vaccine, Prostate cancer, Immunotherapy, Survival, TH1, Prostate-specific antigen, Cetuximab, HPV, Docetaxel, Pharmaceutical industry, Medical imaging, Birth control, H1N1

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Retrieved on: 
Monday, November 13, 2023
Doxorubicin, Squamous-cell carcinoma, Research, Netherlands Cancer Institute, City, Progression-free survival, Sarcoma, BioRxiv, Clinical trial, Patient, Northwestern, MD Anderson Cancer Center, GEIS, Monroe Dunaway Anderson, GSK, PP2A, ASTS, Sarah Cannon Research Institute, SCRI, Cancer, University, Partnership, NKI, Immunotherapy, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.
  • GSK will provide dostarlimab and financial support for the clinical trial.
  • In addition to MD Anderson, the trial also will be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites.

Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

Retrieved on: 
Friday, December 1, 2023
MedImmune, Skin, Research and development, Organization, Food, Public key certificate, RNA interference, Physician, Royal college, Squamous-cell carcinoma, Molecular biology, McGill University, Internal medicine, Therapy, University, Harvard Medical School, Development, Drug development, Pharmaceutical industry, Chiron

and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

Key Points: 
  • and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.
  • Dr. Lebel enters this new role after serving as Senior Vice President for preclinical and clinical development since July 2023.
  • "I am honored to lead Sirnaomics' RNAi pipeline through clinical development, building upon my experiences with the Company, and with outside investigators and international regulatory bodies, I hope my experiences of successfully achieving eight product marketing approvals will bring Sirnaomics to the commercial stage," said Dr. Lebel, M.D., Chief Medical Officer of Sirnaomics.
  • His most recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer Spectrum, where he was responsible for Preclinical and Clinical Development, Regulatory Affairs and Pharmacovigilance/Drug Safety.

Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
Radiation, FDA, Food, Therapy, Prostate Cancer Foundation, Flagship Pioneering, Head, Monroe Dunaway Anderson, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Restart, Partnership, Immunotherapy, University, Squamous-cell carcinoma, MD Anderson Cancer Center, Alpha, Cancer, Patient, Glioblastoma, Alpha Sigma Tau, Neck, Coronavirus Scientific Advisory Board, Pharmaceutical industry

JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.

Key Points: 
  • JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.
  • “I am pleased to welcome Dr. Hahn to the Alpha Tau Scientific Advisory Board at an ideal time in the Company’s growth trajectory,” said Company CEO Uzi Sofer.
  • He previously served as FDA Commissioner from 2019 to 2021, overseeing regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
  • “I have been watching Alpha Tau’s development with excitement for quite some time,” said Dr. Hahn.

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Retrieved on: 
Monday, October 23, 2023
Patient, PD-L1, University of California, Davis, NSCLC, ESMO, Progression-free survival, UC, SCCHN, Pembrolizumab, Congress, Head, MD, PFS, PD-1, Neck, Poster, Non-small-cell lung cancer, Squamous-cell carcinoma, Melanoma, Safety, Toxicity, Pharmaceutical industry

Jonathan Riess, MD, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, shared encouraging clinical and biomarker data from patients with metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥ 50% and recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 CPS ≥ 20.

Key Points: 
  • Jonathan Riess, MD, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, shared encouraging clinical and biomarker data from patients with metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥ 50% and recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 CPS ≥ 20.
  • Dr. Riess commented, “These preliminary data further support the potential of combining IO102-IO103 and pembrolizumab in patients with metastatic NSCLC and recurrent/metastatic SCCHN.
  • The trial is ongoing and continuing to enroll patients in both cohorts.
  • Poster title: A Phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first line (1L) treatment of Non-Small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    The poster will be available on the “ Posters & Publications ” page of the IO Biotech website.